GlassScriptPhysician profile
Lorraine J Spikol
NPI 1932118817
$300.78
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34.99 · 2020: $266.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $57.44 | 2020 | |
| Greenwich Biosciences, INC. | $50.51 | 2020 | |
| Novartis Pharmaceuticals Corporation | $31.77 | 2019-2020 | |
| Amgen INC. | $23.91 | 2020 | |
| Genzyme Corporation | $20.70 | 2020 | |
| Jazz Pharmaceuticals INC. | $20.70 | 2020 | |
| Emd Serono, INC. | $19.01 | 2020 | |
| Harmony Biosciences LLC | $18.42 | 2020 | |
| Ucb, INC. | $16.62 | 2020 | |
| Portola Pharmaceuticals, LLC | $16.46 | 2019 | |
| Sk Life Science, INC. | $13.53 | 2020 | |
| Sunovion Pharmaceuticals INC. | $11.71 | 2020 |
3 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lorraine Spikol listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.